Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.Breast Cancer Research and Treatment|December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancerHope S Rugo, Mike Campbell, Christina Yau, et al.NPJ Breast Cancer|November 21, 2024
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastasesVaseem M Khatri, Mariella A Mestres-Villanueva, Sreenija Yarlagadda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.Ebiomedicine|June 27, 2025
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerMaxwell R Lloyd, Rosario Chica-Parrado, Caroline M Weipert, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 24, 2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter ExperienceSeth A Wander, Hyo S Han, Mark L Zangardi, et al.Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.JCO Precision Oncology|May 4, 2023
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor ProgressionJamie O Brett, Taronish D Dubash, Gabriela N Johnson, et al.JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.Pageof 6